荷载溶瘤病毒细胞载体的研究进展  

Research progress of cell carries carried oncolytic virus

作　　者：方敬敬 唐慧[2] FANG Jing-jing;TANG Hui(College of Medicine,Kunming University of Science and Technology,Kunming 650504;Yunnan Provincial Key Laboratory of Clinical Virology,Kunming Key Laboratory of Tumor Molecular&Immune Prevention,Institute of Basic Medical Sciences,Affiliated Hospital of Kunming University of Science and Technology,the First People s Hospital of Yunnan Province,Kunming 650032,China)

机构地区：[1]昆明理工大学医学院,云南昆明650504 [2]云南省第一人民医院昆明理工大学附属医院临床基础医学研究所云南省临床病毒学重点实验室昆明市肿瘤分子与免疫防治重点实验室,云南昆明650032

出　　处：《基础医学与临床》2018年第12期1761-1765,共5页Basic and Clinical Medicine

基　　金：国家自然科学基金(81460463);云南省中青年学术技术带头人后备人才培养基金(2013HB083);云南省卫生和计划生育委员会医学学科带头人培养基金(D-201642)

摘　　要：溶瘤病毒的给药方式分瘤内注射和静脉注射。静脉注射溶瘤病毒可被免疫系统完全排除而不能发挥其抗肿瘤作用。应用具有淋巴细胞特性、干细胞特性、肿瘤细胞特性的细胞载体荷载并运输溶瘤病毒到达肿瘤部位发挥作用,可更好地发挥抗免疫/肿瘤效应。Oncolytic viruses are intratumorally and intravenously administered.Oncolytic viruses delivered through intravenous injection trend to be eliminated by immune system and fail to exert anti-tumor activity.The anti-immune/tumor effect can be better exerted by cells having lymphocyte and stem cell characteristics and tumor cell characteristics,and transporting oncolytic virus to reach a tumor site.

关 键 词：细胞载体 溶瘤病毒 肿瘤治疗 

分 类 号：R730.5[医药卫生—肿瘤]